# RedHill Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2018

- Company: [RedHill Biopharma Ltd.](/companies/rdhl.md) (CIK 1553846)
- Form: 20-F
- Filed: 2019-02-26
- Accepted by EDGAR: Feb 26, 2019, 12:01 ET
- Period: 2018-12-31
- Accession: 0001558370-19-001037
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1553846/000155837019001037/rdhl-20181231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1553846/000155837019001037/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2018-01-01 to 2018-12-31 | $8.4m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2018-01-01 to 2018-12-31 | $2.8m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2018-01-01 to 2018-12-31 | $5.5m | ifrs-full:GrossProfit |
| Operating income | 12 months, 2018-01-01 to 2018-12-31 | −$39.3m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2018-01-01 to 2018-12-31 | −$38.8m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2018-01-01 to 2018-12-31 | −$0.17 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2018-01-01 to 2018-12-31 | −$0.17 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2018-01-01 to 2018-12-31 | −$34.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2018-01-01 to 2018-12-31 | $23.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2018-12-31 | $29.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2018-12-31 | $56.8m | ifrs-full:CurrentAssets |
| Total assets | at 2018-12-31 | $62.4m | ifrs-full:Assets |
| Current liabilities | at 2018-12-31 | $10.4m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2018-12-31 | $11.2m | ifrs-full:Liabilities |
| Shareholders' equity | at 2018-12-31 | $51.2m | ifrs-full:Equity |
| Shares outstanding | at 2018-12-31 | 283,686,908 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1553846/000155837019001037/rdhl-20181231x20f.htm

Filed Feb 26, 2019.
Source: SEC EDGAR, the filing index for accession 0001558370-19-001037. Last ingested by Listed: Oct 24, 2026, 15:13 ET. No prices; not investment advice.